# US 2024/0201204 A1 · Biomarker and Druggable Target of Neurodegeneration

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0201204 A1
- Document ID: US20240201204A1
- Status: Published application
- Kind: A1
- Application number: 17/790,480
- Filed: 2021-01-07
- Published: 2024-06-20
- Earliest claimed: 2020-01-07
- Assignees: University Hospitals Cleveland Medical Center
- Applicants: University Hospitals Cleveland Medical Center
- Inventors: Andrew A. Pieper; Min-Kyoo Shin; Edwin Vazquez-Rosa
- Web page: https://patentgrep.com/patent/US20240201204A1

## CPC

- G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease}
- A61K 31/335: having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K 31/403: condensed with carbocyclic rings, e.g. carbazole
- A61K 31/603: having further aromatic rings, e.g. diflunisal
- A61K 31/618: having the carboxyl group in position 1 esterified, e.g. salsalate
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- G01N 33/6854: {Immunoglobulins}
- G01N 2333/4709: Amyloid plaque core protein
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

In one aspect, disclosed herein is a method of diagnosing and/or prognosing a neurodegenerative disease in a subject, the method comprising: obtaining a plasma or blood sample from a subject; and detecting a level of acetylated Tau in the plasma or blood sample, wherein a level of acetylated Tau that is at least 25% or 50% higher than a control level in a healthy subject indicates that the subject has a neurodegenerative disease such as traumatic brain injury.

## Claims

### Claim 1

A method of diagnosing and/or prognosing a neurodegenerative disease in a subject, the method comprising:
obtaining a plasma or blood sample from a subject; and
detecting a level of acetylated tau in the plasma or blood sample, wherein a level of acetylated tau that is at least 25% or 50% higher than a control level in a healthy subject indicates that the subject has a neurodegenerative disease such as traumatic brain injury.

### Claim 2 (depends on 1)

The method of claim 1, wherein the obtaining step comprises obtaining a plasma sample from the subject.

### Claim 3 (depends on 2)

The method of claim 2, further comprising depleting albumin and immunoglobulin from the plasma sample.

### Claim 4 (depends on 1)

The method of claim 1, wherein the method does not involve any brain biopsy sample.

### Claim 5 (depends on 1)

The method of claim 1, wherein the detecting step comprises using an antibody or antigen-binding fragment thereof that specifically binds acetylated tau.

### Claim 6 (depends on 5)

The method of claim 5, wherein the antibody is a polyclonal antibody.

### Claim 7 (depends on 5)

The method of claim 5, wherein the antibody is a monoclonal antibody.

### Claim 8

A method of treating a neurodegenerative disease in a subject, the method comprising administering to a subject in need thereof a therapeutically effective amount of an agent that blocks GAPDH S-nitrosylation, inhibits p300/CBP activity, and/or enhances Sirtuin1 activity, whereby accumulation of ac-tau in brain and/or plasma in the subject is reduced.

### Claim 9 (depends on 8)

The method of claim 8, comprising administering a therapeutically effective amount of an inhibitor of GAPDH nitrosylation such as CGP3466B (Omigapil) to the subject.

### Claim 10 (depends on 8)

The method of claim 8, comprising administering a therapeutically effective amount of p300/CBP inhibitor such as salsalate and/or diflunisal to the subject.

### Claim 11 (depends on 10)

The method of claim 10, wherein the salsalate and/or diflunisal is administered at a low, non-anti-neuroinflammatory dose, wherein said dose is 50% or less than an anti-neuroinflammatory dose

### Claim 12 (depends on 11)

The method of claim 11, wherein the low, non-anti-neuroinflammatory dose is about 10-25 mg/kg/day.

### Claim 13 (depends on 11)

The method of claim 11, wherein the anti-neuroinflammatory dose is about 50 mg/kg/day.

### Claim 14 (depends on 9)

The method of claim 9, further comprising co-administering an effective amount of 3,6-dibromo-β-fluoro-N-(3-methoxyphenyl)-9H-carbazole-9-propanamine to the subject.

### Claim 15 (depends on 8)

The method of claim 8, comprising administering an effective amount of 3,6-dibromo-β-fluoro-N-(3-methoxyphenyl)-9H-carbazole-9-propanamine to the subject.

### Claim 16 (depends on 1)

The method of claim 1, wherein the neurodegenerative disease is selected from subarachnoid hemorrhage, schizophrenia, major depression, bipolar disorder, normal aging, epilepsy, traumatic brain injury and/or a visual symptom associated therewith, post-traumatic stress disorder, Parkinson's disease, Alzheimer's disease, Down syndrome, spinocerebellar ataxia, amyotrophic lateral sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of a neuro-active drug, retinal degeneration, spinal cord injury, peripheral nerve injury, physiological weight loss associated with various conditions, cognitive decline and/or general frailty associated with normal aging and/or chemotherapy, chemotherapy induced neuropathy, concussive injury, crush injury, peripheral neuropathy, diabetic neuropathy, post-traumatic headache, multiple sclerosis, retinal degeneration and dystrophy (such as Leber congenital amaurosis, retinitis pigmentosa, cone-rod dystrophy, microphthalmia, anophthalmia, myopia, and hyperopia), spinal cord injury, traumatic spinal cord injury, peripheral nerve injury (such as peripheral nerve crush injury, neonatal brachial plexus palsy, and traumatic facial nerve palsy), retinal neuronal death related diseases (such as glaucoma and age related macular degeneration, diabetic retinopathy, retinal blood vessel occlusions, retinal medication toxicity (such as what amino glycosides or plaquenil can cause), retinal trauma (e.g., post-surgical), retinal infections, choroidal dystrophies, retinal pigmentary retinopathies, inflammatory and cancer mediated auto immune diseases that result in retinal neuronal cell death), Autism, Stargardt disease, Kearns-Sayre syndrome, Pure neurosensory deafness, Hereditary hearing loss with retinal diseases, Hereditary hearing loss with system atrophies of the nervous system, Progressive spinal muscular atrophy, Progressive bulbar palsy, Primary lateral sclerosis, Hereditary forms of progressive muscular atrophy and spastic paraplegia, Frontotemporal dementia, Dementia with Lewy bodies, Corticobasal degeneration, Progressive supranuclear palsy, Prion disorders causing neurodegeneration, Multiple system atrophy (olivopontocerebellar atrophy), Hereditary spastic paraparesis, Friedreich ataxia, Non-Friedreich ataxia, Spinocerebellar atrophies, Amyloidoses, Metabolic-related (e.g., Diabetes) neurodegenerative disorders, Toxin-related neurodegenerative disorders, Multiple sclerosis, Charcot Marie Tooth, Diabetic neuropathy, Metabolic neuropathies, Endocrine neuropathies, Orthostatic hypotension, Creutzfeldt-Jacob Disease, Primary progressive aphasia, Frontotemporal Lobar Degeneration, Cortical blindness, Shy-Drager Syndrome (Multiple, System Atrophy with Orthostatic Hypotension), Diffuse cerebral cortical atrophy of non-Alzheimer type, Lewy-body dementia, Pick disease (lobar atrophy), Thalamic degeneration, Mesolimbocortical dementia of non-Alzheimer type, Nonhuntingtonian types of chorea and dementia, Cortical-striatal-spinal degeneration, Dementia-Parkinson-amyotrophic lateral sclerosis complex, Cerebrocerebellar degeneration, Cortico-basal ganglionic degeneration, Familial dementia with spastic paraparesis or myoclonus, and Tourette syndrome.

### Claim 17

An apparatus for diagnosing and/or prognosing a neurodegenerative disease in a subject, comprising:
a support material; and
an antibody or antigen-binding fragment thereof that specifically binds acetylated tau, wherein said antibody or antigen-binding fragment thereof is adsorbed in or associated with the support material.

### Claim 18 (depends on 17)

The apparatus of claim 17, wherein the antibody is a polyclonal antibody.

### Claim 19 (depends on 17)

The apparatus of claim 17, wherein the antibody is a monoclonal antibody.

### Claim 20 (depends on 8)

The method of claim 8, wherein the neurodegenerative disease is selected from subarachnoid hemorrhage, schizophrenia, major depression, bipolar disorder, normal aging, epilepsy, traumatic brain injury and/or a visual symptom associated therewith, post-traumatic stress disorder, Parkinson's disease, Alzheimer's disease, Down syndrome, spinocerebellar ataxia, amyotrophic lateral sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of a neuro-active drug, retinal degeneration, spinal cord injury, peripheral nerve injury, physiological weight loss associated with various conditions, cognitive decline and/or general frailty associated with normal aging and/or chemotherapy, chemotherapy induced neuropathy, concussive injury, crush injury, peripheral neuropathy, diabetic neuropathy, post-traumatic headache, multiple sclerosis, retinal degeneration and dystrophy (such as Leber congenital amaurosis, retinitis pigmentosa, cone-rod dystrophy, microphthalmia, anophthalmia, myopia, and hyperopia), spinal cord injury, traumatic spinal cord injury, peripheral nerve injury (such as peripheral nerve crush injury, neonatal brachial plexus palsy, and traumatic facial nerve palsy), retinal neuronal death related diseases (such as glaucoma and age related macular degeneration, diabetic retinopathy, retinal blood vessel occlusions, retinal medication toxicity (such as what amino glycosides or plaquenil can cause), retinal trauma (e.g., post-surgical), retinal infections, choroidal dystrophies, retinal pigmentary retinopathies, inflammatory and cancer mediated auto immune diseases that result in retinal neuronal cell death), Autism, Stargardt disease, Kearns-Sayre syndrome, Pure neurosensory deafness, Hereditary hearing loss with retinal diseases, Hereditary hearing loss with system atrophies of the nervous system, Progressive spinal muscular atrophy, Progressive bulbar palsy, Primary lateral sclerosis, Hereditary forms of progressive muscular atrophy and spastic paraplegia, Frontotemporal dementia, Dementia with Lewy bodies, Corticobasal degeneration, Progressive supranuclear palsy, Prion disorders causing neurodegeneration, Multiple system atrophy (olivopontocerebellar atrophy), Hereditary spastic paraparesis, Friedreich ataxia, Non-Friedreich ataxia, Spinocerebellar atrophies, Amyloidoses, Metabolic-related (e.g., Diabetes) neurodegenerative disorders, Toxin-related neurodegenerative disorders, Multiple sclerosis, Charcot Marie Tooth, Diabetic neuropathy, Metabolic neuropathies, Endocrine neuropathies, Orthostatic hypotension, Creutzfeldt-Jacob Disease, Primary progressive aphasia, Frontotemporal Lobar Degeneration, Cortical blindness, Shy-Drager Syndrome (Multiple, System Atrophy with Orthostatic Hypotension), Diffuse cerebral cortical atrophy of non-Alzheimer type, Lewy-body dementia, Pick disease (lobar atrophy), Thalamic degeneration, Mesolimbocortical dementia of non-Alzheimer type, Nonhuntingtonian types of chorea and dementia, Cortical-striatal-spinal degeneration, Dementia-Parkinson-amyotrophic lateral sclerosis complex, Cerebrocerebellar degeneration, Cortico-basal ganglionic degeneration, Familial dementia with spastic paraparesis or myoclonus, and Tourette syndrome.
